Início › Leucemia Linfocítica Crônica › Carolina do Norte

Ensaios clínicos de Leucemia Linfocítica Crônica em Carolina do Norte

34 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Carolina do Norte.

Cidades em Carolina do Norte

Texto oficial do estudo (Inglês)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham
Margaret R Pardee Memorial Hospital, Hendersonville

RecrutandoFase 3

Idades 65 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

AdventHealth Infusion Center Asheville, Asheville
Southeastern Medical Oncology Center-Clinton, Clinton
AdventHealth Infusion Center Haywood, Clyde
e mais 6

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, Charlotte
Research Site, Winston-Salem

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06542250

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Southeastern Medical Oncology Center-Clinton, Clinton
Southeastern Medical Oncology Center-Goldsboro, Goldsboro
e mais 5

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

GC2202 Study Site 109, Greenville
GC2202 Decentralized Study Site 114, Morrisville
GC2202 Study Site 117, Wilson

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

University of North Carolina At Chapel Hill, Chapel Hill
Levine Cancer Center, Charlotte
Atrium Health Wake Forest Baptist, Winston-Salem

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06943872

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Atrium Health Levine Cancer Institute (Lci), Charlotte
Duke University Medical Center, Durham

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of North Carolina At Chapel Hill, Chapel Hill
Atrium Health Levine Cancer Institute (Lci), Charlotte
Duke University Medical Center, Durham
e mais 1

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Carolina Oncology Specialists, PA ( Site 0054), Charlotte
Southeastern Medical Oncology Center ( Site 0049), Goldsboro

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06136559

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Duke University, Durham

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Duke University, Durham
Novant Health Cancer Institute, Winston-Salem

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, Charlotte
Research Site, Charlotte

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06564038

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

UNC School of Medicine, Division of Hematology, Chapel Hill

RecrutandoFase 1/2

Idades 12 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT04588922

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill

RecrutandoFase 1/2

Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Research Site, Charlotte
Research Site, Durham
Research Site, Winston-Salem

RecrutandoFase 2

Idades de 18 a 130 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT07024706

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

University of North Carolina at Chapel Hill, Chapel Hill

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 31 de jul. de 2026 · NCT06708897

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Duke University Medical Center, Durham

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT05131022

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

North Carolina Basnight Cancer Hospital, Chapel Hill

Recrutando

Idades 18 e acima · Todos os sexos · Atualizado em 1 de jul. de 2026 · NCT06860880

Registry of Older Patients With Cancer

Seby B. Jones Cancer Center, Boone
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
East Carolina University, Greenville
e mais 4

RecrutandoEstudo observacional

Idades 65 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT01137825

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

East Carolina University, Greenville

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06588478

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

University of North Carolina, Chapel Hill

RecrutandoFase 1

Idades 13 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04771572

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Wake Forest Baptist Health, Winston-Salem

RecrutandoEstudo observacional

Idades de 18 a 120 · Todos os sexos · Atualizado em 13 de abr. de 2026 · NCT01890486

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Atrium Health /ID# 267219, Charlotte
Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Duke University Medical Center, Durham

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Duke University Medical Center, Durham

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

Duke University, Durham

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

University of North Carolina /ID# 233313, Chapel Hill
Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 9 de fev. de 2026 · NCT04895436

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

The University of North Carolina at Chapel Hill, Chapel Hill

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 7 de jan. de 2026 · NCT06043674

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Duke University, Durham

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 10 de dez. de 2025 · NCT05602363

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

RecrutandoEstudo observacional

Idades de 18 a 120 · Todos os sexos · Atualizado em 27 de out. de 2025 · NCT01137643

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Durham VA Medical Center, Durham, NC, Durham

RecrutandoFase 2

Idades de 18 a 80 · Todos os sexos · Atualizado em 14 de out. de 2025 · NCT06520098

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

University of North Carolina, Chapel Hill

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2025 · NCT05780034

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Duke University, Durham

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 17 de jul. de 2025 · NCT04704323

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.